Participated · Equity · Oct 2025

Egetis Therapeutics is a publicly traded company on Nasdaq Stockholm. The firm recently strengthened its balance sheet through an oversubscribed directed share issue that brought in approximately SEK 183 million before transaction costs. In the transaction, the company issued 35,923,812 new common shares at a subscription price of SEK 5.10 per share, reflecting a 4.9 percent discount to the closing price on 2 October 2025. The capital raise attracted both Swedish and international investors, including Frazier Life Sciences, Invus, Petrichor, Woodline Partners LP, Fjärde AP-fonden and Linc AB. Proceeds from the financing increase the company’s financial flexibility for its ongoing corporate activities. The oversubscription signals strong market confidence in the company and its future prospects.

Participated · Series C · Jan 2025

Geneoscopy leverages a proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform to develop diagnostic tests for gastrointestinal diseases. Its lead product, ColoSense, is an FDA-approved at-home, stool-based colorectal cancer screening test for average-risk individuals over age 45. The company pairs its RNA isolation platform with Bio-Rad’s Droplet Digital PCR (ddPCR) technology to achieve high sensitivity and specificity. Geneoscopy plans to launch and commercialize ColoSense and is working with Labcorp to provide broad availability so providers can order the test within screening programs. The firm is also investing in an innovative pipeline of diagnostic tests for inflammatory bowel disease, including tools for treatment selection and therapy monitoring. The recent financing is positioned to support commercialization, regulatory milestones, and continued product development. Geneoscopy is a St. Louis, MO–based life sciences company focused on developing diagnostic tests for gastrointestinal health. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. The device was awarded Breakthrough Device Designation from the US FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Preliminary trials suggest the diagnostic can detect these lesions at a higher rate than existing noninvasive screening tests. The company intends to use recent funding to support the U.S. CRC-PREVENT pivotal trial, scale commercial infrastructure, and expand its diagnostic product pipeline. Andrew Barnell is the company's CEO. Geneoscopy is a life sciences company focused on developing diagnostic tests for gastrointestinal (GI) health. Its lead product is a colorectal cancer (CRC) screening test that quantifies eukaryotic RNA isolated from epithelial cells in stool to detect CRC and advanced adenomas. The company announced an oversubscribed $6.9 million Series A and plans to use the proceeds to advance the CRC screening test. The financing was led by Cultivation Capital and NT Investments, with Lightchain Capital LLC as a significant investor. Following the round, Bobby W. Sandage, Jr., Najeeb Thomas, and Drew Dennison are joining Geneoscopy’s board of directors. Geneoscopy highlights that stool-derived eukaryotic RNA biomarkers are highly sensitive for both cancer and precancerous lesions, and it intends to pursue other applications of its platform technology.

Participated · Equity · Apr 2024

Evergreen Theragnostics is a Springfield, NJ–based clinical-stage radiopharmaceutical company led by CEO James Cook. The company focuses on developing diagnostic and therapeutic radiopharmaceuticals and operates a Contract Development and Manufacturing (CDMO) business. It intends to commercialize its diagnostic agent Octevy™, subject to FDA approval, and to advance its novel theragnostic pair EVG-321 (Lutetium-177 and Gallium-68) into registration-enabling clinical trials, targeting small cell lung cancer. The company will use new funding to expand operations, bolster R&D, progress its discovery pipeline into clinical trials, and grow CDMO services. Proceeds will also support drug discovery and commercialization of proprietary products. Evergreen Theragnostics operates across three core areas—CDMO, products, and drug discovery—focusing on radiopharmaceuticals for cancer patients. Founded in 2019 and based in Springfield, NJ, the company is led by President and CEO James Cook. Evergreen raised $15M in a Series B to prepare for a potential commercial launch of Ga-68 DOTATOC, planning to build commercial capabilities, hire staff, and build inventory. The Ga-68 DOTATOC product is intended to be available through Evergreen’s radiopharmacy partners around the country if approved. Using the capital raise, the company is launching a new business unit, Evergreen Discovery, to develop novel radiopharmaceuticals and has recruited Dr. Thomas Reiner as Chief Scientific Officer. Evergreen Discovery will be based in a new research facility near Princeton, NJ, opening in Q3'2023.

Led · Series A · May 2023

Ascend offers CMC services including process development, clinical GMP manufacturing, analytics and regulatory support for advanced modality biotech companies, with an initial technical focus on high‑quality AAV vectors. The company assembled a cross‑functional team of approximately 120 experts by acquiring and merging experienced teams across three countries and two continents. Its technology base uses a split two‑plasmid transfection system for AAV manufacture and a broad suite of assays. Ascend’s operations are headquartered in the UK, with GMP production in Potters Bar (North London), platform research in the San Francisco Bay Area, and process development and analytics in Munich. The business launched alongside a $132.5M Series A, which has enabled the acquisition of CMC capabilities and technologies from Freeline Therapeutics and provides operational runway to build the company. Management says it will continue to refine and flex its model to meet market needs and is presenting capabilities at industry meetings such as ASGCT.

Led · Equity · Jan 2023

Vero Biotech develops Genosyl, an FDA-approved portable, tankless system that delivers a constant concentration of inhaled nitric oxide for cardiac patients in acute settings, targeting persistent pulmonary hypertension in newborns. The device is intended to eliminate the need for large nitric oxide tanks in neonatal intensive care units, which are costly and labor-intensive. Vero says it is currently generating revenue and has raised nearly $300 million to date. Company leadership reports a rapid uptake in demand for Genosyl and is focused on ramping commercial deployment. Management plans to use new funding to support continued commercial expansion, increase device-building spend, and advance other R&D initiatives. Board director Todd Brady indicated the financing will enable faster market deployment. Vero Biotech is a commercial-stage healthcare company focused on neonatal intensive care and the acute care hospital community. Its core product is the GENOSYL Delivery System (DS), a tankless, portable inhaled nitric oxide (iNO) delivery system engineered with redundant backup features, an easy-to-use interface, and portability. The third generation of the GENOSYL DS was recently approved by the FDA. The company intends to use the proceeds from its recent financing to support further development and commercialization of GENOSYL DS. Vero Biotech raised $30M in funding in a round led by Petrichor, and Petrichor partner Patrick Lally has joined the company's board. The company is led by CEO and President Brent V. Furse and is based in Atlanta, GA. Vero Biotech LLC is an Atlanta, Georgia–based biotechnology company focused on the design, development and commercialization of next‑generation products for patients with pulmonary and cardiac diseases. Led by CEO Brent V. Furse, the company developed the GENOSYL Delivery System (GENOSYL DS), an inhaled nitric oxide delivery system that is approved by the U.S. FDA. The GENOSYL DS delivers nitric oxide, a vasodilator used in care of patients with adult respiratory distress syndrome and persistent pulmonary hypertension of the neonate. The system was authorized by the FDA for expanded emergency use for patients with cardiopulmonary complications associated with COVID‑19, was granted an emergency IND for at‑home use, and is approved for interhospital transport in ground, fixed‑wing and rotary‑wing environments. The company closed a $50M senior secured term loan from Runway Growth Capital, providing additional financing. Vero Biotech was formerly known as GeNO LLC.